Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...

Eli Lilly & Co has experienced a significant stock price decline of 18.64% over the past week, largely due to disappointing ...

William “Bill” Joseph Cruser, 80, of Greenwood, IN passed away Tuesday, August 5, 2025, at Community Hospital South in ...

Eli Lilly and Company (NYSE:LLY) is one of the 14 Best Aggressive Growth Stocks to Buy According to Analysts. On July 29, BMO ...

Now, Eli Lilly says its experimental GLP-1 pill is a success after the first phase-three trial. The company said more than 3,000 adults on the experimental oral medication lowered their weight by an ...

Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

Eli Lilly and Company (LLY) is currently at $634.33, down $6.53 or 1.02% --Would be lowest close since Jan. 25, 2024, when it closed at $627.62 --Worst four day stretch since the four days ending Oct.

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...